Hepatitis Testing Markets
Hepatitis Testing MarketsHepatitis infection remains a significant challenge for the medical community. According to the CDC, around 2.7 million people in the United States have a chronic HCV infection or nearly 1% of the population.
Hepatitis Testing Markets Includes:
- Hepatitis Immunoassay Market, 2016 - 2021
- Hepatitis Molecular Testing Market, 2016 -2021
- Hepatitis Point of Care Markets, 2016-2021
- Molecular Testing Market by Type (C, B, A and Others)
- Key Trends in the Market
- Geographic Breakout of Market (US, ROW)
- Company Profiles
Molecular diagnostics is unrivaled among the IVD technologies used for infectious disease testing in terms of its performance and applicability. Microarray, next-generation sequencing and development-stage isothermal amplification methods represent promising contributions to the market space. For the time being, PCR and isothermal amplification tests represent the bulk of the market with assay development proceeding faster than ever using genomic science tools, microfluidics, machine automation, and novel forms of results detection. Immunoassays are more often used for the initial detection of hepatitis infections, but with the increasing significance of hepatitis in healthcare and the development of sophisticated antiviral therapeutics, molecular tests are becoming just as integral to clinical hepatitis treatment.
Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).
Please note that your term must be at least three characters long and numbers will be blocked by the # sign.